ORAMED PHARMACEUTICALS INC. overview

Oramed Pharmaceuticals Issues Letter to Shareholders PR Newswire NEW YORK, March 4, 2025 Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials. Distribution of majority of Oramed's holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech's public listing. Cash dividend planned ( ~$0.25 per share). Marketing Authorization Application has been...

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin PR Newswire NEW YORK, Feb. 11, 2025 New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq. OraTech will have global marketing rights to Oramed's POD™ oral protein delivery technology. HTIT...

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt PR Newswire NEW YORK, Oct. 7, 2024 NEW YORK , Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the execution of definitive agreements for the restructuring of a portion of its existing Senior Secured Promissory Note from Scilex Holding Company (Nasdaq: SCLX)...

Oramed Letter to Shareholders PR Newswire NEW YORK, June 26, 2024 Stock Repurchase Program Scilex Senior Secured Note Phase 3 Oral Insulin Trial in US JV with Chinese Partner, HTIT NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed") ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron . Dear...

Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock PR Newswire NEW YORK, June 26, 2024 NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value...

Oramed Letter to Shareholders PR Newswire NEW YORK, Feb. 20, 2024 Initiating Phase 3 oral insulin trial in the United States under a new protocol JV with Chinese Partner, HTIT Scilex Senior Secured Note PeriTech Asset Purchase & Strategic Out-licensing NEW YORK , Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to...

Thinking about buying stock in MicroAlgo, Oramed Pharmaceuticals, Limbach Holdings, Niu Technologies, or Applied Molecular Transport? PR Newswire NEW YORK, Sept. 22, 2023 NEW YORK , Sept. 22, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MLGO, ORMP, LMB, NIU, and AMTI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. MLGO:...

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company PR Newswire NEW YORK, Sept. 21, 2023 18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously announced Stock Purchase Agreement and DIP Term Loan with Sorrento Therapeutics NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:...